Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Kansas Genglycos Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of KansasPolicy N/A

    Genglycos Coverage for Glycogen Storage Disease Type Ia

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical prior authorization, dosing, administration, and coverage criteria for Genglycos, an intravenous gene therapy for Blue Cross and Blue Shield of Kansas members with glycogen storage disease type Ia (GSDIa), subject to member benefit contracts and applicable mandates.

    Policy Summary
    PayerBlue Cross Blue Shield of Kansas
    PolicyGenglycos Coverage for Glycogen Storage Disease Type Ia
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 26, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation, including diagnostic testing, laboratory results, and step-therapy documentation, before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 doseInitial prior authorization validity
    Not renewableRenewal authorization status
    Age 8+Minimum age for initial approval
    1 kitMaximum dose quantity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    GSDIa
    Covered indication

    Coverage Criteria

    Initial therapy for GSDIa

    Covered for initial therapy when all of the following criteria are met.

    Initial GSDIa approval

    • Eligibility: Member is at least 8 years of age and does not have an FDA-labeled contraindication to Genglycos, such as severe hepatic fibrosis or cirrhosis.Age ≥8 years
    • Diagnostic confirmation

      • Molecular diagnosis: Biallelic pathogenic variants in the G6PC1 gene are identified by molecular genetic testing.
      • Enzyme diagnosis: Deficient hepatic glucose-6-phosphatase catalytic activity is demonstrated from a liver biopsy specimen.
    • Nutritional therapy: Member is receiving therapeutic cornstarch or an equivalent regimen following international guidelines or recommendations, has stable nutrition, glycemic, and clinical status, and will use Genglycos to reduce daily cornstarch intake as an adjunct to nutritional management.
    • Immunologic eligibility: Member does not have detectable anti-AAV8 antibody titers at baseline.Undetectable baseline anti-AAV8 titers
    • Adrenal assessment and monitoring: Adrenal function will be assessed by clinical examination and laboratory testing including morning serum cortisol and ACTH before therapy and as clinically indicated.
    • Liver assessment and monitoring: Liver function will be assessed by clinical examination and ALT, AST, and total bilirubin before therapy, every 2 to 4 weeks until month 6, and as clinically indicated.Every 2–4 weeks through month 6
    • Post-treatment safety plan: Member will use immunosuppressive corticosteroid therapy following Genglycos and will be monitored for hepatotoxicity, adrenal insufficiency, and adrenal crisis.
    • Additional exclusions absent: Member does not have pre-existing hepatic impairment or acute hepatic viral infection, has not received prior AAV vector-based gene therapy, and has not received a liver transplant.

    Renewal criteria

    Renewal is not available.

    Renewal: Prior authorization is initially valid for one dose and may not be renewed.One dose only

    Coverage is not approved when the member has an FDA-labeled contraindication to Genglycos, including severe hepatic fibrosis or cirrhosis. The member must also have undetectable baseline anti-AAV8 antibody titers, no pre-existing hepatic impairment or acute hepatic viral infection, no history of prior AAV vector-based gene therapy, and no prior liver transplant.

    Coding and Dose Parameters

    HCPCS codesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals (Hospital Outpatient Use Only)
    NDCNDC
    69794-0333-03Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 15 to <21 kg; 6 mL total dose; 3 vials
    69794-0334-04Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 21 to <27 kg; 8 mL total dose; 4 vials
    69794-0335-05Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 27 to <33 kg; 10 mL total dose; 5 vials
    69794-0336-06Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 33 to <39 kg; 12 mL total dose; 6 vials
    69794-0337-07Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 39 to <45 kg; 14 mL total dose; 7 vials
    69794-0338-08Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 45 to <51 kg; 16 mL total dose; 8 vials
    69794-0339-09Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 51 to <57 kg; 18 mL total dose; 9 vials
    69794-0340-10Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 57 to <63 kg; 20 mL total dose; 10 vials
    69794-0341-11Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 63 to <69 kg; 22 mL total dose; 11 vials
    69794-0342-12Genglycos 3.0 × 10^13 genome copies (gc) per mL, 2 mL single-dose vial; 69 to <75 kg; 24 mL total dose; 12 vials
    1–10 of 13
    1/2
    Minimum Age
    Minimum ageAt least 8 years
    Applies toInitial Genglycos therapy for GSDIa
    Coverage contextMember must also meet all other applicable approval criteria
    Maximum Dose Quantity
    Maximum quantity1 kit per dose
    Vials per kit15 vials
    Total volume per dose30 mL

    Provider Requirements and Denial Risks

    Prior Authorization

    One-Time Prior Authorization

    Prior authorization is approved for one dose only. The authorization is not renewable; submit no renewal request for additional doses.

    • Initial authorization validity: one dose
    • Renewal: not permitted
    Step Therapy

    Cornstarch Therapy Prerequisite

    Before requesting Genglycos, confirm that the member is receiving therapeutic cornstarch or an equivalent regimen in accordance with applicable international guidelines and has stable nutritional, glycemic, and clinical status. Genglycos is used to reduce daily cornstarch intake as an adjunct to nutritional management.

    • Therapeutic cornstarch or equivalent regimen required
    • Stable nutritional, glycemic, and clinical status required

    Disease Background

    Glycogen storage disease type Ia (GSDIa), also known as von Gierke disease, is associated with pathogenic variants in the G6PC1 gene or deficient hepatic glucose-6-phosphatase catalytic activity. Under this policy, Genglycos is used as an adjunct to nutritional management for eligible members receiving a stable therapeutic cornstarch-based regimen who need to reduce daily cornstarch intake.

    Key Definitions

    GSDIa
    ConditionGlycogen storage disease type Ia (GSDIa), also known as von Gierke disease
    Molecular confirmationBiallelic pathogenic variants in the G6PC1 gene identified by molecular genetic testing
    Alternative confirmationDeficient hepatic glucose-6-phosphatase catalytic activity demonstrated from a liver biopsy specimen
    Anti-AAV8 Antibody Titers
    DefinitionAntibodies directed against adeno-associated virus, serotype 8 (anti-AAV8)
    Baseline requirementNo detectable anti-AAV8 antibody titers at baseline
    Coverage implication

    Initial Therapy

    Initial GSDIa therapy

    Genglycos is covered for initial treatment of eligible members with GSDIa when all policy criteria are satisfied.

    Initial Genglycos treatment: Member is at least 8 years old; has confirmed GSDIa; is receiving stable therapeutic cornstarch or equivalent nutritional therapy; has undetectable baseline anti-AAV8 antibodies; completes required adrenal and liver assessments; will receive post-treatment immunosuppressive corticosteroids and monitoring; and has none of the listed hepatic, viral, prior-gene-therapy, or transplant exclusions.Age ≥8 years

    Continuation and Renewal

    No renewal

    Continuation authorization is not available.

    Continuation: The policy authorizes only one dose and does not permit renewal.One dose

    Prerequisite Therapy

    StepRequirementCoverage
    1Member must be receiving therapeutic cornstarch or an equivalent regimen following international guidelines or recommendations, with stable nutrition, glycemic control, and clinical status. Genglycos is used to reduce daily cornstarch intake as an adjunct to nutritional management.Required

    Dose Quantity Limit

    Quantity Limit
    DrugGenglycos
    Maximum quantity1 kit per dose
    Kit contents15 vials totaling 30 mL

    Administration Site and Method

    Note

    Administer in an infusion center

    Administer Genglycos as a single-dose intravenous infusion through a peripheral venous catheter. Premedicate with acetaminophen and non-sedating antihistamines 30 to 60 minutes before infusion.

    • Administration setting: infusion center.
    Policy Summary
    PayerBlue Cross Blue Shield of Kansas
    PolicyGenglycos Coverage for Glycogen Storage Disease Type Ia
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNovember 26, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation, including diagnostic testing, laboratory results, and step-therapy documentation, before treatment.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Dose ParametersProvider Requirements and Denial RisksDisease BackgroundKey DefinitionsInitial TherapyContinuation and RenewalPrerequisite TherapyDose Quantity LimitAdministration Site and Method
    Liver Monitoring Frequency
    Laboratory testsAlanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin
    Before therapyAssess liver function before the start of therapy
    Ongoing frequencyEvery 2 to 4 weeks until month 6, and as clinically indicated
    Documentation Required

    Clinical Documentation Required

    Submit supporting clinical documentation with every authorization request. Records are reviewed at submission to establish medical necessity and must support the diagnosis, applicable step-therapy or nutritional requirements, clinical markers, and initiation of treatment.

    • Include medical records, chart notes, laboratory results, and confirmatory diagnostics as applicable
    • Document genetic or mutational testing and other clinical markers when applicable
    • Submit through the prior authorization web portal or by fax
    Documentation Required

    Diagnostic Confirmation

    Document GSDIa (von Gierke disease) through qualifying diagnostic evidence. Approval requires either molecular confirmation or deficient hepatic enzyme activity documented from a liver biopsy specimen.

    • Biallelic pathogenic variants in the G6PC1 gene identified by molecular genetic testing; or
    • Deficient hepatic glucose-6-phosphatase catalytic activity demonstrated from a liver biopsy specimen
    Documentation Required

    Baseline Safety Assessments

    Complete and document required baseline safety assessments before therapy. The member must have no detectable anti-AAV8 antibody titers, adrenal function assessed, and liver function assessed before treatment; liver monitoring continues every 2 to 4 weeks through month 6 and as clinically indicated.

    • Baseline anti-adeno-associated virus serotype 8 (anti-AAV8) antibody testing must be negative or undetectable
    • Assess adrenal function with clinical examination, morning serum cortisol, and ACTH
    • Assess liver function with clinical examination, ALT, AST, and total bilirubin before treatment and every 2 to 4 weeks until month 6
    • Use immunosuppressive corticosteroid therapy following Genglycos and monitor for hepatotoxicity, adrenal insufficiency, and adrenal crisis
    Documentation Required

    Current Nutritional Therapy

    Document that the member remains on therapeutic cornstarch or an equivalent nutritional regimen consistent with international guidelines, with stable nutritional, glycemic, and clinical status, before initiating Genglycos.

    • Record the current nutritional regimen and stability of nutritional, glycemic, and clinical status
    • Confirm planned use of Genglycos to reduce daily cornstarch intake as an adjunct to nutritional management
    Denial Risk

    Incomplete Documentation May Result in Denial

    Incomplete supporting records or missing diagnostic documentation may result in denial because medical necessity cannot be established under the policy.

    • Provide records at the time of submission
    • Missing medical records, chart notes, laboratory results, confirmatory diagnostics, or required genetic and clinical-marker documentation may prevent approval
    Denial Risk

    Contraindications and Exclusion Conditions

    Coverage is not approved when required eligibility conditions are absent or an exclusion applies. Confirm all exclusion criteria before submitting the request.

    • Member must be at least 8 years of age
    • Member must not have FDA-labeled contraindications, including severe hepatic fibrosis or cirrhosis
    • No pre-existing hepatic impairment or acute hepatic viral infection
    • No prior AAV vector-based gene therapy
    • No prior liver transplant
    Denial Risk

    Improper Administration Method

    Administer Genglycos as a single-dose intravenous infusion through a peripheral venous catheter. Do not administer it by intravenous push or bolus.

    • Premedicate with acetaminophen and a non-sedating antihistamine 30 to 60 minutes before infusion
    • Vials should not be thawed or punctured until immediately before use
    • If same-day administration is not expected, store the product as specified in the prescribing information
    Billing Rule

    Quantity Above Dose Limit

    Do not request or bill quantities above the policy dosing limit for a single dose.

    • Maximum: 1 kit
    • Maximum: 15 vials
    • Maximum total volume: 30 mL per dose
    • Each vial contains 2 mL at 3.0 × 1013 genome copies/mL
    Detectable baseline anti-AAV8 antibody titers are an exclusion from coverage